{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T08:33:36Z","timestamp":1794904416425,"version":"4.9.1"},"reference-count":29,"publisher":"American Society of Hematology","issue":"5","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,3,12]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>Hospitalized patients with inflammatory bowel disease (IBD) are at increased risk of venous thromboembolism (VTE). We aimed to evaluate the effectiveness and safety of prophylactic anticoagulation compared with no anticoagulation in hospitalized patients with IBD. We conducted a retrospective cohort study using a hospital-based database. We included patients with IBD who had a length of hospital stay \u22652\u00a0days between 1 January 2016 and 31 December 2019. We excluded patients who had other indications for anticoagulation, users of direct oral anticoagulants, warfarin, therapeutic-intensity heparin, and patients admitted for surgery. We defined exposure to prophylactic anticoagulation using charge codes. The primary effectiveness outcome was VTE. The primary safety outcome was bleeding. We used propensity score matching to reduce potential differences between users and nonusers of anticoagulants and Cox proportional-hazards regression to estimate adjusted hazard ratios (HRs) and 95% confidence intervals (CIs). The analysis included 56 194 matched patients with IBD (users of anticoagulants, n\u00a0= 28 097; nonusers, n\u00a0= 28 097). In the matched sample, prophylactic use of anticoagulants (vs no use) was associated with a lower rate of VTE (HR, 0.62; 95%\u00a0CI, 0.41-0.94) and with no difference in the rate of bleeding (HR, 1.05; 95%\u00a0CI, 0.87-1.26). In this study of hospitalized patients with IBD, prophylactic use of heparin was associated with a lower rate of VTE without increasing bleeding risk compared with no anticoagulation. Our results suggest potential benefits of prophylactic anticoagulation to reduce the burden of VTE in hospitalized patients with IBD.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/bloodadvances.2023011756","type":"journal-article","created":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T18:07:25Z","timestamp":1704132445000},"page":"1272-1280","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":10,"title":["Effectiveness and safety of prophylactic anticoagulation among hospitalized patients with inflammatory bowel disease"],"prefix":"10.1182","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7982-7419","authenticated-orcid":false,"given":"Ghadeer K.","family":"Dawwas","sequence":"first","affiliation":[{"name":"1Division of Epidemiology, Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN"},{"name":"2Center for Clinical Epidemiology and Biostatistics, Department of Biostatistics, Epidemiology, and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3595-5697","authenticated-orcid":false,"given":"Adam","family":"Cuker","sequence":"additional","affiliation":[{"name":"3Departments of Medicine and Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas E.","family":"Schaubel","sequence":"additional","affiliation":[{"name":"2Center for Clinical Epidemiology and Biostatistics, Department of Biostatistics, Epidemiology, and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3107-3862","authenticated-orcid":false,"given":"James D.","family":"Lewis","sequence":"additional","affiliation":[{"name":"2Center for Clinical Epidemiology and Biostatistics, Department of Biostatistics, Epidemiology, and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA"},{"name":"4Division of Gastroenterology and Hepatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2024,3,4]]},"reference":[{"issue":"5","key":"2024031114201514000_bib1","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1053\/j.gastro.2023.07.003","article-title":"Incidence, prevalence, and racial and ethnic distribution of inflammatory bowel disease in the United States","volume":"165","author":"Lewis","year":"2023","journal-title":"Gastroenterology"},{"issue":"2","key":"2024031114201514000_bib2","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/S0025-6196(12)65200-8","article-title":"Vascular complications of inflammatory bowel disease","volume":"61","author":"Talbot","year":"1986","journal-title":"Mayo Clin Proc"},{"issue":"4","key":"2024031114201514000_bib3","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1038\/s41424-018-0013-8","article-title":"Risk of thrombosis and mortality in inflammatory bowel disease","volume":"9","author":"Andrade","year":"2018","journal-title":"Clin Transl Gastroenterol"},{"issue":"9","key":"2024031114201514000_bib4","doi-asserted-by":"crossref","first-page":"2272","DOI":"10.1111\/j.1572-0241.2008.02052.x","article-title":"Rising prevalence of venous thromboembolism and its impact on mortality among hospitalized inflammatory bowel disease patients","volume":"103","author":"Nguyen","year":"2008","journal-title":"Am J Gastroenterol"},{"issue":"3","key":"2024031114201514000_bib5","first-page":"779","article-title":"Inflammatory bowel disease is a risk factor for recurrent venous thromboembolism","volume":"139","author":"Novacek","year":"2010","journal-title":"Gastroenterology 1943"},{"issue":"1","key":"2024031114201514000_bib6","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1046\/j.1572-0241.2003.04026.x","article-title":"Venous thromboembolism in inflammatory bowel disease","volume":"99","author":"Solem","year":"2004","journal-title":"Am J Gastroenterol"},{"issue":"4","key":"2024031114201514000_bib7","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1016\/0016-5085(94)90741-2","article-title":"Platelets circulate in an activated state in inflammatory bowel disease","volume":"106","author":"Collins","year":"1994","journal-title":"Gastroenterology"},{"issue":"9715","key":"2024031114201514000_bib8","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/S0140-6736(09)61963-2","article-title":"Venous thromboembolism during active disease and remission in inflammatory bowel disease: A cohort study","volume":"375","author":"Grainge","year":"2010","journal-title":"Lancet"},{"issue":"12","key":"2024031114201514000_bib9","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.3748\/wjg.v26.i12.1231","article-title":"Venous thromboembolism in inflammatory bowel disease","volume":"26","author":"Cheng","year":"2020","journal-title":"World J Gastroenterol"},{"issue":"10","key":"2024031114201514000_bib10","doi-asserted-by":"crossref","first-page":"e479","DOI":"10.1016\/j.crohns.2013.03.002","article-title":"Predictors and safety of venous thromboembolism prophylaxis among hospitalized inflammatory bowel disease patients","volume":"7","author":"Ra","year":"2013","journal-title":"J Crohns Colitis"},{"issue":"4","key":"2024031114201514000_bib11","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1097\/MIB.0000000000000007","article-title":"Venous thromboembolism in patients with","volume":"20","author":"Scoville","year":"2014","journal-title":"Inflamm Bowel Dis"},{"issue":"7","key":"2024031114201514000_bib12","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1161\/01.CIR.0000138928.83266.24","article-title":"Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients","volume":"110","author":"Leizorovicz","year":"2004","journal-title":"Circulation"},{"key":"2024031114201514000_bib13","author":"Premier Healthcare Database","year":"2020"},{"issue":"9","key":"2024031114201514000_bib14","doi-asserted-by":"crossref","first-page":"2592","DOI":"10.1007\/s10620-009-1074-z","article-title":"Validation of ICD-9-CM diagnostic codes for inflammatory bowel disease among veterans","volume":"55","author":"Thirumurthi","year":"2010","journal-title":"Dig Dis Sci"},{"issue":"1","key":"2024031114201514000_bib15","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.jacc.2019.01.011","article-title":"2019 AHA\/ACC\/HRS focused update of the 2014 AHA\/ACC\/HRS guideline for the management of patients with atrial fibrillation: a report of the american college of cardiology\/american heart association task force on clinical practice guidelines and the heart rhythm society","volume":"74","author":"January","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"2024031114201514000_bib16","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.thromres.2010.03.009","article-title":"Evaluation of the predictive value of ICD-9-CM coded administrative data for venous thromboembolism in the united states","volume":"126","author":"White","year":"2010","journal-title":"Thromb Res"},{"issue":"6","key":"2024031114201514000_bib17","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1002\/pds.2109","article-title":"An automated database case definition for serious bleeding related to oral anticoagulant use","volume":"20","author":"Cunningham","year":"2011","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"25","key":"2024031114201514000_bib18","doi-asserted-by":"crossref","first-page":"3083","DOI":"10.1002\/sim.3697","article-title":"Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples","volume":"28","author":"Austin","year":"2009","journal-title":"Stat Med"},{"issue":"12","key":"2024031114201514000_bib19","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1038\/nbt1209-1135","article-title":"How does multiple testing correction work?","volume":"27","author":"Noble","year":"2009","journal-title":"Nat Biotechnol"},{"issue":"6","key":"2024031114201514000_bib20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15226\/2374-815X\/4\/6\/001105","article-title":"Trends in hospitalization and in-hospital mortality with inflammatory bowel disease complicated by venous thromboembolism","volume":"4","author":"Shah","year":"2017","journal-title":"J Gastroenterol Pancreatol Liver Disord"},{"issue":"10","key":"2024031114201514000_bib21","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1111\/apt.12294","article-title":"Meta-analysis: the risk of venous thromboembolism in patients with inflammatory bowel disease","volume":"37","author":"Yuhara","year":"2013","journal-title":"Aliment Pharmacol Ther"},{"issue":"6","key":"2024031114201514000_bib22","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.crohns.2013.09.021","article-title":"Thromboembolic events and cardiovascular mortality in inflammatory bowel diseases: a meta-analysis of observational studies","volume":"8","author":"Fumery","year":"2014","journal-title":"J Crohns Colitis"},{"issue":"3","key":"2024031114201514000_bib23","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1053\/j.gastro.2014.01.042","article-title":"Consensus statements on the risk, prevention, and treatment of venous thromboembolism in inflammatory bowel disease: Canadian association of gastroenterology","volume":"146","author":"Nguyen","year":"2014","journal-title":"Gastroenterology"},{"issue":"12","key":"2024031114201514000_bib24","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1038\/s41575-021-00492-8","article-title":"International consensus on the prevention of venous and arterial thrombotic events in patients with inflammatory bowel disease","volume":"18","author":"Olivera","year":"2021","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"22","key":"2024031114201514000_bib25","doi-asserted-by":"crossref","first-page":"3198","DOI":"10.1182\/bloodadvances.2018022954","article-title":"American society of hematology 2018 guidelines for management of venous thromboembolism: prophylaxis for hospitalized and nonhospitalized medical patients","volume":"2","author":"Sch\u00fcnemann","year":"2018","journal-title":"Blood Adv"},{"issue":"2","key":"2024031114201514000_bib26","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s11605-010-1396-3","article-title":"A nationwide analysis of changes in severity and outcomes of inflammatory bowel disease hospitalizations","volume":"15","author":"Ananthakrishnan","year":"2011","journal-title":"J Gastrointest Surg"},{"issue":"6","key":"2024031114201514000_bib27","first-page":"578","article-title":"Venous thromboembolism prophylaxis in inflammatory bowel disease flare-ups","volume":"32","author":"Kaddourah","year":"2019","journal-title":"Ann Gastroenterol"},{"issue":"8","key":"2024031114201514000_bib28","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1155\/2007\/924257","article-title":"Hospitalization-based major comorbidity of inflammatory bowel disease in canada","volume":"21","author":"Bernstein","year":"2007","journal-title":"Can J Gastroenterol"},{"issue":"4","key":"2024031114201514000_bib29","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s40256-020-00456-4","article-title":"Real-world comparative effectiveness and cost comparison of thromboprophylactic use of enoxaparin versus unfractionated heparin in 376,858 medically ill hospitalized US patients","volume":"21","author":"Veeranki","year":"2021","journal-title":"Am J Cardiovasc Drugs"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/5\/1272\/2217640\/blooda_adv-2023-011756-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/5\/1272\/2217640\/blooda_adv-2023-011756-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,11]],"date-time":"2024-03-11T14:20:40Z","timestamp":1710166840000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/8\/5\/1272\/506904\/Effectiveness-and-safety-of-prophylactic"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,4]]},"references-count":29,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,3,12]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2023011756","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,4]]}}}